Part XV · Supportive care, survivorship, and patient experience · Chapter 86
Psychosocial care and lived experience
The part of the illness that no staging system records.
1 · Distress, anxiety, depression, and fear of recurrence
Distress is not one thing, and treating it as one is why screening for it so often leads nowhere. Clinical depression, situational anxiety, existential distress and fear of recurrence have different courses and different treatments. A single-item thermometer detects the presence of something. It does not say which.
Fear of recurrence deserves separating from the rest because it behaves differently. It does not resolve with time in the way acute distress does, it spikes predictably around scans and anniversaries, and it is not irrational. A patient who has been told her disease can return after fifteen years is responding accurately to the information in Dormancy, residual disease, and late recurrence.
That has a practical consequence. Reassurance that recurrence is unlikely does not work, because the patient already knows the number. What helps is usually a plan for what happens if it does, which converts an unbounded fear into a bounded one.
Screening for distress without a route to treatment produces a record of unmet need rather than a reduction in it. The failure is almost always in the referral pathway rather than in the instrument.
2 · Body image and identity
Body image after breast cancer is not vanity, and framing it as cosmetic is the commonest way clinicians dismiss it. Surgery, reconstruction, alopecia, weight change, lymphedema and induced menopause each alter a different aspect of how a patient recognises herself.
The clinically useful distinction is between changes a patient chose and changes that happened to her. A reconstruction she selected and a hair loss she did not are both alterations of appearance, and they are not equivalent psychologically. Choice is doing much of the work.
Reconstruction improves body image on average and does not reliably improve it in any given patient. Presenting it as a solution to distress rather than as an option with its own morbidity sets up a second disappointment.
3 · Family, partner, and caregiver experience
Caregiver burden is measurable and it is not measured. Partners of patients with metastatic disease carry sustained anticipatory grief, often while managing the practical logistics that make treatment possible.
Social connection is not a soft variable. In a prospective cohort, socially isolated women had worse outcomes after breast cancer diagnosis than socially integrated women1. The mechanisms by which isolation acts on physiology are developed in Host and tumor interactions and in2, so this is a biological finding as much as a psychosocial one.
Children of patients are the group most reliably overlooked. Their needs are developmental rather than informational, and the parent is rarely in a position to assess them.
4 · Work, disability, and social participation
Work is a treatment variable. It determines insurance in some systems, it structures the day, and losing it removes an identity that the diagnosis has already destabilised.
Return to work depends on the nature of the work more than on the stage of the disease. Physical occupations, shift work and roles without schedule flexibility are the hardest to hold through treatment. Cognitive symptoms after chemotherapy matter most in jobs that depend on sustained attention.
Financial consequences follow, and they are clinical. Financial toxicity is a validated patient-reported outcome3, and financial insolvency after a cancer diagnosis is associated with higher mortality4. That association is developed in Access, affordability, and financial toxicity.
5 · Patient-reported outcomes as routine clinical data
Clinicians systematically underestimate symptom burden compared with what patients report. The gap is largest for symptoms that are subjective and chronic, which is most of what endocrine therapy causes.
Routine collection of patient-reported outcomes changes that, but only when three conditions hold. The reports must reach the clinician before or during the visit. Someone must be responsible for acting on a threshold breach. And the instrument must be short enough to complete every time.
Systems that collect without acting generate data and no benefit. This is the same implementation problem as in Implementation, policy, and quality of care, appearing at the level of a single clinic.
6 · Advocacy, peer support, and the metastatic visibility gap
Breast cancer advocacy changed research funding, trial design and the language of consent, and it did so faster than the profession did. That history belongs in History of breast cancer.
The gap it left is metastatic disease. Awareness campaigns are built around survivorship and completion, and a patient who will be treated indefinitely does not fit that story. Patients living with metastatic disease report feeling excluded from the movement organised in their disease's name.
The practical form of that exclusion is research funding and trial availability weighted toward early disease, and support services designed around finishing treatment. A survivorship programme that assumes an end date has nothing to offer someone in year nine of continuous therapy. That population is addressed directly in Survivorship in metastatic disease, living long with incurable cancer.
References
All 4 references
- Kroenke CH, Kubzansky LD, Schernhammer ES, Holmes MD, Kawachi I. Social networks, social support, and survival after breast cancer diagnosis. J Clin Oncol 2006 24:1105-1111. PMID 16505430
- Cacioppo JT, Cacioppo S, Capitanio JP, Cole SW. The neuroendocrinology of social isolation. Annu Rev Psychol 2015 66:733-767. PMID 25148851
- de Souza JA, Yap BJ, Wroblewski K, et al. Measuring financial toxicity as a clinically relevant patient-reported outcome: the validation of the COmprehensive Score for financial Toxicity (COST). Cancer 2017 123:476-484. PMID 27716900
- Ramsey SD, Bansal A, Fedorenko CR, et al. Financial insolvency as a risk factor for early mortality among patients with cancer. J Clin Oncol 2016 34:980-986. PMID 26811521